Pakistan’s Advantage in Hepatitis Delta & MASH Trials
Pakistan’s Advantage in Hepatitis Delta & MASH Trials
16 PagesThis white paper explores Pakistan’s growing role in global Hepatitis Delta and MASH clinical research. It highlights the country’s high disease burden, treatment-naïve patient populations, and strong recruitment performance in international trials. The paper details regulatory reforms, digital submission processes, and globally aligned oversight that support efficient trial execution. It also emphasizes experienced investigators, accredited trial sites, and strong patient engagement. The paper concludes that Pakistan offers a unique combination of access, speed, and expertise for sponsors developing therapies in complex liver diseases.
